Danone has unveiled Oikos Fusion, a new yogurt drink designed to help users of GLP-1 weight loss drugs such as Ozempic maintain and rebuild muscle mass. The launch marks the dairy giant’s latest push to position its Oikos brand at the center of functional nutrition.
The Paris-based company noted that about 10% of the U.S. population has tried or is currently using GLP-1 drugs, which often result in muscle loss. According to the American College of Lifestyle Medicine, roughly 20% of the weight lost while on these medications comes from muscle.
“Oikos Fusion is a one-of-a-kind opportunity, bringing something new to the yogurt category. GLP-1 is the center of the bullseye for this proposition,” said Rafael Acevedo, president of yogurt at Danone North America.
The new cultured dairy drink combines whey protein, leucine, and vitamin D — a blend aimed at supporting muscle synthesis, strength maintenance, and digestive health. Each 7-ounce bottle delivers 23 grams of complete protein, 5 grams of prebiotic fiber, and vitamins B3 and B12. Flavors include strawberry, mixed berry, and vanilla.
Oikos Fusion will debut this month at Walmart, followed by a nationwide rollout in October at Target, Kroger, and Wakefern.
The product is expected to appeal not only to GLP-1 users but also to fitness-conscious consumers looking for high-protein, gut-friendly options. Its formulation draws on Danone’s existing expertise in specialized nutrition, helping the company accelerate product development.
Oikos, already one of Danone’s fastest-growing U.S. brands, posted 40% retail sales growth in 2024 and surpassed $1 billion in annual sales for the first time. Earlier this year, Danone entered the $7 billion protein shake market with shelf-stable Oikos Protein Shakes, further cementing its focus on functional, on-the-go nutrition.
“With Oikos Fusion, we’re staying true to what the brand stands for — high protein, science-backed nutrition, and relevance for today’s health-conscious consumer,” Acevedo said.